Merck & Co
MRK
143.63
-2.32
-1.59%
Merck & Co
US · MRK
#43 by market cap
Listed 1970
143.63
-2.32
-1.59%
Live - 5344 symbols - heartbeat 21s ago
· 2026-10-20 08:29
Recent news
-
Morgan Stanley Maintains Merck & Co(MRK.US) With Buy Rating, Cuts Target Price to $177Market Newswire · 2026/10/7
-
Rating change
Morgan Stanley Maintains Merck & Co(MRK.US) With Buy Rating, Maintains Target Price $179Market Newswire · 2026/9/21
-
Company notice
MRK Holdings: Marco Co., Ltd. has obtained certification as a "Gender‑Friendly Plus" business operator in Osaka Prefecture.JPX · 2026/9/11
-
Rating change
BofA Securities Maintains Merck & Co(MRK.US) With Buy Rating, Maintains Target Price $166Market Newswire · 2026/9/23
-
BMO Capital Maintains Merck & Co(MRK.US) With Buy Rating, Maintains Target Price $170Market Newswire · 2026/10/8
-
UBS Maintains Merck & Co(MRK.US) With Buy Rating, Maintains Target Price $175Market Newswire · 2026/10/9
-
Company notice
MRK Holdings: Notice: "A Musical Hour for Adults," hosted by MISEL Co., Ltd.JPX · 2026/7/10
-
Rating change
TD Cowen Maintains Merck & Co(MRK.US) With Hold Rating, Raises Target Price to $155Market Newswire · 2026/9/23
-
Company notice
MRK Holdings: Notice of the "Live Entertainment Show ~You & I~" hosted by MISEL Co., Ltd.JPX · 2026/7/10
-
Cantor Fitzgerald Maintains Merck & Co(MRK.US) With Hold Rating, Raises Target Price to $145Market Newswire · 2026/10/8
-
Rating change
J.P. Morgan Maintains Merck & Co(MRK.US) With Buy Rating, Announces Target Price $165Market Newswire · 2026/10/5
-
Rating change
Scotiabank Maintains Merck & Co(MRK.US) With Buy Rating, Raises Target Price to $180Market Newswire · 2026/9/29
-
BofA Securities Maintains Merck & Co(MRK.US) With Buy Rating, Cuts Target Price to $163Market Newswire · 2026/10/9
-
Company notice
MRK Holdings: Notice of Corporate Logo Change for MRK Holdings Co., Ltd.JPX · 2026/10/1
-
Rating change
Scotiabank Maintains Merck & Co(MRK.US) With Buy Rating, Maintains Target Price $155Market Newswire · 2026/9/23
-
Rating change
RBC Capital Maintains Merck & Co(MRK.US) With Hold Rating, Maintains Target Price $150Market Newswire · 2026/10/1
-
Company notice
MRK Holdings: Matters concerning controlling shareholders, etc.JPX · 2026/6/15
-
Rating change
Goldman Sachs Maintains Merck & Co(MRK.US) With Buy Rating, Maintains Target Price $160Market Newswire · 2026/10/1
-
Rating change
Analysts Offer Insights on Healthcare Companies: Prime Medicine, Inc. (PRME) and Merck & Company (MRK)TipRanks · 2026/9/25
-
Rating change
DBS Maintains Merck & Co(MRK.US) With Buy Rating, Raises Target Price to $180Market Newswire · 2026/9/12
-
Rating change
Leerink Partners Maintains Merck & Co(MRK.US) With Buy Rating, Maintains Target Price $161Market Newswire · 2026/9/10
-
Rating change
Barclays Downgrades Merck & Co(MRK.US) to Hold Rating, Raises Target Price to $174.46Market Newswire · 2026/9/8
-
Rating change
Guggenheim Maintains Merck & Co(MRK.US) With Buy Rating, Raises Target Price to $170Market Newswire · 2026/9/8
-
UBS Maintains Merck & Co(MRK.US) With Buy Rating, Maintains Target Price $175Market Newswire · 2026/9/24
-
BMO Capital Maintains Merck & Co(MRK.US) With Buy Rating, Maintains Target Price $170Market Newswire · 2026/9/25
Headlines are aggregated automatically and are not independently verified or edited by our team.
Quote time 2026-10-20 08:29:32 · For reference only, not investment advice and not tailored to your situation.
the keytruda patent cliff is a few years out but the market’s already discounting it hard. pipeline needs to deliver or this stays cheap for a while, that’s the whole debate in one sentence.